All In Biotech

Drug Trial Radar · NCT06570798

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jul 16, 2025

Primary completion

Aug 6, 2028

Study completion Aug 6, 2028

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Aug 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).

Conditions

  • Systemic Lupus Erythematosus
  • Active Refractory Rheumatoid Arthritis

Interventions

  • InebilizumabDrug

    IV Infusion

  • BlinatumomabDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Day 1 to Week 52
  2. Subprotocol A, B Part A, and C Part A: Number of Participants Who Experience a Serious TEAETime frame: Day 1 to Week 52
  3. Subprotocol B Part B Subgroup 1: Number of Participants With Complete Renal Response (CRR)Time frame: Week 52
  4. Subprotocol B Part B Subgroup 2: Number of Participants With Remission in SLE as Defined by Definition of Remission in SLE (DORIS)Time frame: Week 26
  5. Subprotocol C Part B: Percentage of Participants Achieving Disease Activity Score-28 Joint C-Reactive Protein (DAS28-CRP) RemissionTime frame: Week 12

Locations

58 sites in 10 countries. Site status is shown where the registry gives one.

  • HonorHealth Research and Innovation Institute

    Scottsdale, Arizona · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Vida Research Center

    Hialeah, Florida · Terminated

  • Homestead Associates In Research Inc

    Homestead, Florida · Terminated

  • Vitaly Clinical Research

    Miami, Florida · Terminated

  • Bioresearch Partner Coral Terrace

    South Miami, Florida · Recruiting

  • University Medical Center New Orleans

    New Orleans, Louisiana · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Northwell Health

    Great Neck, New York · Recruiting

  • Westchester Medical Center

    Hawthorne, New York · Completed

  • Columbia University Medical Center

    New York, New York · Recruiting

  • University of Rochester Medical Center

    Rochester, New York · Recruiting

  • MetroHealth Medical Center

    Cleveland, Ohio · Recruiting

  • The Metro Health System Main Campus

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Prolato Clinical Research Center

    Houston, Texas · Completed

  • Seattle Rheumatology Associates

    Seattle, Washington · Recruiting

  • Linear Clinical Research Limited

    Perth, Western Australia, Australia · Recruiting

  • Cliniques Universtaire Saint Luc Universite Catholique de Louvain

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Gent

    Ghent, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven - Campus Gasthuisberg

    Leuven, Belgium · Recruiting

  • Centre Hospitalier Universitaire de Liege - Sart Tilman

    Liège, Belgium · Recruiting

  • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre

    Le Kremlin-Bicêtre, France · Recruiting

  • Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez

    Lille, France · Recruiting

  • Centre Hospitalier Universitaire de Lyon- Hopital Edouard Herriot

    Lyon, France · Recruiting

  • Centre Hospitalier Universitaire de Lyon - Hopital Edouard Herriot

    Lyon Cédex 3, France · Recruiting

  • Hopital de la Conception

    Marseille, France · Recruiting

  • Hopital Cochin

    Paris, France · Recruiting

  • Hopital Bichat Claude Bernard

    Paris, France · Terminated

  • Hopital Europeen Georges Pompidou

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil

    Strasbourg, France · Recruiting

  • Centre Hospitalier Universitaire de Strasbourg - Hopital de Hautepierre

    Strasbourg, France · Recruiting

  • Centre Hospitalier Universitaire de Toulouse - Hopital Purpan

    Toulouse, France · Recruiting

  • Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil

    Toulouse, France · Recruiting

  • Krankenhaus Porz am Rhein gGmbH

    Cologne, Germany · Recruiting

  • Universitaetsklinikum Duesseldorf AoeR

    Düsseldorf, Germany · Recruiting

  • Universitaetsklinikum Leipzig

    Leipzig, Germany · Recruiting

  • Klinikum der LMU Muenchen

    München, Germany · Completed

  • IRCCS Ospedale San Raffaele

    Milan, Italy · Terminated

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.